1. Cell Cycle/DNA Damage Epigenetics NF-κB Apoptosis Metabolic Enzyme/Protease Immunology/Inflammation
  2. HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species
  3. Sulforaphane

Sulforaphane  (Synonyms: 萝卜硫素)

目录号: HY-13755 纯度: 98.19%
COA 产品使用指南

Sulforaphane 是一种具有口服活性的 Keap1/Nrf2/ARE 诱导剂。Sulforaphane 能促进肿瘤抑制蛋白的转录,并有效地抑制 HDACs 的活性。Sulforaphane 通过激活 Keap1/Nrf2/ARE 途径,以及进一步诱导 HO-1 的表达保护心脏。Sulforaphan 通过 AMPK 依赖性信号传导抑制高糖诱导的胰腺癌。Sulforaphane 具有抗癌和抗炎活性。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Sulforaphane Chemical Structure

Sulforaphane Chemical Structure

CAS No. : 4478-93-7

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
5 mg ¥375
In-stock
10 mg ¥600
In-stock
25 mg ¥1350
In-stock
50 mg ¥2500
In-stock
100 mg ¥4500
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Sulforaphane:

注册 MCE会员完成审核
即刻享有 积分商城 300 专属积分

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 33 篇科研文献

WB
IF

    Sulforaphane purchased from MCE. Usage Cited in: Eur J Pharmacol. 2021 Aug 7;174412.  [Abstract]

    Western blotting analysis shows that CIBP can significantly induce the protein expression of Nrf2 and HO-1 in the spinal cord and that intrathecal administration of Sulforaphane (SFN) can further promoted the protein expression of Nrf2 and HO-1 protein.

    Sulforaphane purchased from MCE. Usage Cited in: Eur J Pharmacol. 2021 Aug 7;174412.  [Abstract]

    Immunofluorescence histochemistry confirmes that Sulforaphane (SFN) treatment further increased Nrf2 and HO-1 expression in the dorsal horn of the spinal cord of CIBP rats.

    Sulforaphane purchased from MCE. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334.  [Abstract]

    Western blot detection of Nrf2, TLR4, IRF1, iNOS, and ARG-1 levels following Sulforaphane (SFN; 10 μM or 20 μM) treatment or Nrf2 upregulation/downregulation in BMDMs co-cultured with COM-stimulated TECs. SFN treatment activates Nrf2 expression, which then downregulates the expression of TLR4, IRF1, and iNOS and upregulates the expression of ARG-1.

    Sulforaphane purchased from MCE. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334.  [Abstract]

    The distribution of iNOS (green) and ARG-1 (red) in BMDMs according to immunofluorescence. Sulforaphane (SFN; 10 μM or 20 μM) decreases iNOS and increases ARG-1 levels.

    Sulforaphane purchased from MCE. Usage Cited in: Vascul Pharmacol. 2018 Oct;109:56-71.  [Abstract]

    A representative western blot analysis gel showing the reduces abundance of eNOS relative to GAPDH in tissues cultured under hyperglycaemic conditions (25 mM glucose: 25) versus either freshly isolated tissues (F, first lane on left) or tissues cultured under euglycaemic conditions (10 mM glucose: 10). The abundance of eNOS is preserved for tissues cultured in 25 mM glucose along with 1 μM Sulforaphane (25+S).
    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties[1][2][3][4][5][6].

    IC50 & Target[1]

    HDAC

     

    Bax

     

    Caspase-3

     

    体外研究
    (In Vitro)

    Sulforaphane (0-30 μM) 以剂量依赖性方式引发细胞周期停滞和细胞凋亡 (apoptosis)。这种由 Sulforaphane 诱导的细胞周期停滞与细胞周期蛋白 A 和 B1 的表达增加有关[1]
    Sulforaphane (0-30 μM) 能抑制 HT29 细胞的生长再启动,降低细胞活性,对分化的细胞具有较低的毒性[1]
    Sulforaphane (10 μM, 24 小时) 预处理 H9c2 细胞后,可以减少凋亡细胞数量,降低促凋亡蛋白 (Baxcaspase-3细胞色素 c) 的表达,并抵消 Doxorubicin (HY-15142A) (1 μM, 2 小时) 引发的线粒体膜电位增加[2]
    Sulforaphane (10 μM, 2 或 24 小时) 通过激活 Keap1/Nrf2/ARE 途径,以及进一步诱导 HO-1 的表达,能有效地减少 Doxorubicin (1 μM, 2 或 24 小时) 诱导的 H9c2 细胞中 ROS 的产生和细胞凋亡[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[2]

    Cell Line: H9c2 cells
    Concentration: Sulforaphane: 10 μM; Doxorubicin: 1 μM
    Incubation Time: Sulforaphane: 2h; Doxorubicin: 2, 24h
    Result: Prevented the release of cytochrome c into the cytosol.
    Prevented the translocation of Bax into the cytosol.
    Attenuated the doxorubicin-induced increase in the levels of cleaved caspase-3.
    Induced a significant increase in HO-1 protein expression.
    Induced a significantly higher level of Nrf2 expression in the nucleus compared to the cytoplasm.

    Apoptosis Analysis[2]

    Cell Line: H9c2 cells
    Concentration: Sulforaphane: 10 μM; Doxorubicin: 1 μM
    Incubation Time: Sulforaphane: 2h; Doxorubicin: 24h
    Result: Protected the H9c2 cells against doxorubicin-induced cell death.
    Increased cell viability in a dose-dependent manner.
    Significantly reduced the number of apoptotic cells treated with Doxorubicin.

    RT-PCR[2]

    Cell Line: H9c2 cells
    Concentration: Sulforaphane: 10 μM; Doxorubicin: 1 μM
    Incubation Time: Sulforaphane: 2, 24h; Doxorubicin: 2, 24h
    Result: Induced heme oxygenase-1 (HO-1) mRNA expression in a dose-dependent manner.
    体内研究
    (In Vivo)

    Sulforaphane (13.3, 17.7, 26.6 mg/kg; 灌胃; 5 天) 能抑制雌性 Sprague-Dawley 大鼠接受 DMBA (HY-W011845) (8 mg/mL) 单次剂量处理后乳腺肿瘤的形成[3]
    Sulforaphane (13.3, 26.6 mg/kg; 灌胃; 5 天) 能减少由 DMBA (8 mg/mL) 在雌性 Sprague-Dawley 大鼠中诱发的乳腺肿瘤的发生率、多发性和重量,并延迟其发展[3]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female Sprague-Dawley rat[3]
    Dosage: Sulforaphane: 13.3, 17.7, 26.6 mg/kg; DMBA (HY-W011845): 8 mg/mL
    Administration: Oral gavage; 5 days
    Result: Prevented the occurrence of tumors in a dose-dependent manner.
    Significantly reduced the incidence of tumors.
    Clinical Trial
    分子量

    177.29

    Formula

    C6H11NOS2

    CAS 号
    性状

    液体

    颜色

    Colorless to light yellow

    中文名称

    萝卜硫素;莱菔硫烷

    结构分类
    初始来源
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    -20°C, sealed storage, away from moisture and light

    *该产品在溶液状态不稳定,建议您现用现配,即刻使用。

    溶解性数据
    In Vitro: 

    DMSO 中的溶解度 : ≥ 62.5 mg/mL (352.53 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    H2O 中的溶解度 : 50 mg/mL (282.02 mM; 超声助溶)

    * "≥" means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 5.6405 mL 28.2024 mL 56.4048 mL
    5 mM 1.1281 mL 5.6405 mL 11.2810 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。

    * 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    In Vivo:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (14.10 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (14.10 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      20% SBE-β-CD in Saline 的配制(4°C,储存一周):2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

    以下溶解方案,请直接配置工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂: 30 % SBE-β-CD

      Solubility: 10 mg/mL (56.40 mM); 澄清溶液; 超声助溶

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    计算结果
    工作液所需浓度 : mg/mL
    该产品水溶性佳,请具体参考实测 水 / PBS / Saline 中的溶解度数据。
    您所需的储备液浓度超过该产品的实测溶解度,如有需要,请与 MCE 中国技术支持联系。
    纯度 & 产品资料

    纯度: 99.75%

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 5.6405 mL 28.2024 mL 56.4048 mL 141.0119 mL
    5 mM 1.1281 mL 5.6405 mL 11.2810 mL 28.2024 mL
    10 mM 0.5640 mL 2.8202 mL 5.6405 mL 14.1012 mL
    15 mM 0.3760 mL 1.8802 mL 3.7603 mL 9.4008 mL
    20 mM 0.2820 mL 1.4101 mL 2.8202 mL 7.0506 mL
    25 mM 0.2256 mL 1.1281 mL 2.2562 mL 5.6405 mL
    30 mM 0.1880 mL 0.9401 mL 1.8802 mL 4.7004 mL
    40 mM 0.1410 mL 0.7051 mL 1.4101 mL 3.5253 mL
    50 mM 0.1128 mL 0.5640 mL 1.1281 mL 2.8202 mL
    60 mM 0.0940 mL 0.4700 mL 0.9401 mL 2.3502 mL
    80 mM 0.0705 mL 0.3525 mL 0.7051 mL 1.7626 mL
    100 mM 0.0564 mL 0.2820 mL 0.5640 mL 1.4101 mL

    * 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Sulforaphane
    目录号:
    HY-13755
    需求量: